LOVFF (Cannara Biotech) Gross-Profit-to-Asset % : 27.57% (As of Aug. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cannara Biotech Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Cannara Biotech's annualized Gross Profit for the quarter that ended in Aug. 2024 was $30.62 Mil. Cannara Biotech's average Total Assets over the quarter that ended in Aug. 2024 was $111.08 Mil. Therefore, Cannara Biotech's annualized Gross-Profit-to-Asset % for the quarter that ended in Aug. 2024 was 27.57%.

Cannara Biotech Gross-Profit-to-Asset % Historical Data

The historical data trend for Cannara Biotech's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cannara Biotech Gross-Profit-to-Asset % Chart

Cannara Biotech Annual Data

Trend

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

Gross-Profit-to-Asset %

Get a 7-Day Free Trial

1.99

14.28

15.76

19.98

Cannara Biotech Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial															27.61	22.82	11.48	18.78	27.57

Competitive Comparison of Cannara Biotech's Gross-Profit-to-Asset %

For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cannara Biotech's Gross-Profit-to-Asset % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Cannara Biotech's Gross-Profit-to-Asset % falls into.

Cannara Biotech Gross-Profit-to-Asset % Calculation

Cannara Biotech's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Aug. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Aug. 2024 )	/	( (Total Assets (A: Aug. 2023 )	+	Total Assets (A: Aug. 2024 ))	/ count )
	=	21.814	/	( (105.002	+	113.306)	/ 2 )
	=	21.814	/	109.154
	=	19.98 %

Cannara Biotech's annualized Gross-Profit-to-Asset % for the quarter that ended in Aug. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Aug. 2024 )	/	( (Total Assets (Q: May. 2024 )	+	Total Assets (Q: Aug. 2024 ))	/ count )
	=	30.62	/	( (108.852	+	113.306)	/ 2 )
	=	30.62	/	111.079
	=	27.57 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Aug. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Cannara Biotech Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Cannara Biotech's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cannara Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cannara Biotech Inc (OTCPK:LOVFF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

8CB0:Germany LOVE:Canada

Address

1055 West Georgia Street, Suite 2050, Vancouver, BC, CAN, V6E 3P3

Website

http://www.cannara.ca

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .